Core Insights - Marimekko's net sales and operating profit increased in the third quarter of 2025, with net sales reaching EUR 50.8 million, an 8% increase from EUR 47.2 million in the same period of 2024 [7][11] - The company expects net sales for 2025 to grow from EUR 182.6 million in 2024, with a comparable operating profit margin estimated at 16-19% [4][18] Financial Performance - In Q3 2025, net sales increased by 8% to EUR 50.8 million, driven by a 15% rise in wholesale sales [7][11] - Operating profit for Q3 improved to EUR 12.5 million, a 13% increase from EUR 11.1 million in Q3 2024, with a comparable operating profit of EUR 12.7 million [6][12] - For the January-September period, net sales grew by 5% to EUR 134.8 million, with operating profit rising to EUR 23.1 million [7][13] Market and Sales Insights - International sales accounted for 46% of total net sales in Q3 2025, with both wholesale and retail sales contributing to the growth [6][7] - The company reported a 3% increase in net sales in Finland, supported by positive retail sales development [7][13] - Marimekko's brand sales outside Finland decreased by 16% in Q3 2025 compared to the previous year [8] Strategic Developments - The company is focusing on expanding its international presence, particularly in Asia, with plans to open 10-15 new stores in 2025 [20][21] - Marimekko launched a French-language online store in August 2025, ahead of the opening of its first Paris flagship store [17] - The company continues to invest in its brand and customer community through various events and exhibitions, including the "Field of Flowers" exhibition [14][15] Future Outlook - The company anticipates challenges in 2025 due to uncertainties in the global economy, including geopolitical tensions and consumer behavior [18][19] - Licensing income is expected to be significantly lower in 2025 compared to the previous year, impacting overall net sales [22] - Fixed costs are projected to rise in 2025, influenced by general cost inflation and increased marketing expenses [23]

Company Overview - PTT Exploration and Production Public Company Limited is a Thailand-based petroleum exploration and production (E&P) company operating in approximately 30 countries, including Algeria, Australia, Canada, Indonesia, and New Zealand [1] - The company's exploration and production operations account for over 90% of its revenue [1] Performance Metrics - The company's Profitable Growth rank is 4, which is a decline from the previous period's 3rd rank, indicating a below-average performance compared to 290 large energy companies worldwide [4] - The Profitability rank is 3, which is better than its Growth rank of 6, but has decreased from the prior period's 2nd rank, showing above-average performance compared to peers [4] - The Growth rank of 6 has also declined from the previous period's 4th rank, indicating below-average performance compared to peers [4]

Financial Data and Key Metrics Changes - In Q3 2025, the company reported sales of EUR 12.4 billion, representing a 7% increase compared to the previous year [4] - Business EPS reached EUR 2.91, reflecting a robust growth of EUR 0.19 or 13% compared to Q3 2024 [15] - The gross margin increased by 2.3 percentage points this quarter, driven by an improved product mix and productivity gains [13] Business Line Data and Key Metrics Changes - Pharmaceutical sales grew by 7% at constant exchange rates, primarily driven by immunology and recent launches [13] - New product launches contributed EUR 1.8 billion in sales this quarter, accounting for 15% of total sales [6] - Dupixent sales reached EUR 4 billion for the first time, with a 26% growth this quarter [7][15] Market Data and Key Metrics Changes - Vaccine sales were EUR 3.4 billion, reflecting a decrease due to competitive price pressure and lower flu immunization rates in the U.S. [8] - Outside the U.S., Dupixent sales grew by 21%, exceeding EUR 1 billion in the quarter [8] - Beyfortus sales increased by 20% this quarter, now available in 40 countries [9] Company Strategy and Development Direction - The company aims to improve access to treatments and lower prices for patients, as demonstrated by the expansion of its patient affordability program for insulins [5][11] - The focus remains on innovation in respiratory vaccines and expanding the commercial portfolio with new product launches [10][11] - The company is committed to maintaining a balanced capital allocation policy, focusing on organic growth, selective acquisitions, and progressive dividends [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business outlook for the remainder of the year and reiterated full-year sales guidance [4] - The company anticipates continued growth momentum, with expectations for high single-digit sales growth and low double-digit business EPS growth at constant exchange rates for the full year [15][16] - Management acknowledged challenges in the vaccine segment but remains committed to innovation and improving patient access [10][11] Other Important Information - The company has achieved a milestone of treating 1 million patients for non-communicable diseases across low and middle-income countries since 2021 [11] - The company has completed acquisitions of Drensbios DR0201, Vigil Neuroscience, and Blueprint, with associated costs factored into guidance [15] Q&A Session Summary Question: Update on Poly-SPMS regulatory debate and confidence in resolving FDA questions - Management confirmed ongoing conversations with the FDA and submitted data sets, looking forward to the PDUFA date of December 28 [32] Question: Update on U.S. policy conversations - Management stated that dialogues with the U.S. government have been ongoing and focused on demonstrating the value the company can bring [38] Question: Q4 ordering trends for Beyfortus - Management confirmed expectations for Q4 performance to be similar to Q3, with a focus on increasing vaccination coverage rates in the U.S. [42][44] Question: Insights on Dupixent's COPD development and gross to net dynamics - Management highlighted strong growth in COPD and indicated that gross to net dynamics are monitored and included in long-term guidance [81] Question: Timing dynamics around riliprubart and other programs under review - Management indicated that timelines for riliprubart are being updated and that data from various studies will be presented at relevant scientific congresses [62] Question: Potential for product acquisitions and vaccine trends - Management acknowledged the success of Dupixent and indicated a cautious approach to M&A, while also addressing concerns about vaccine fatigue [90]

Financial Data and Key Metrics Changes - In Q3 2025, the company reported sales of €12.4 billion, representing a 7% increase compared to the previous year [4] - The business gross margin increased by 2.3 percentage points, driven by an improved product mix and productivity gains [13] - Business EPS reached €2.91, reflecting a robust growth of €0.19 or 13% compared to Q3 2024 [15] Business Line Data and Key Metrics Changes - Pharmaceutical sales grew by 7% at constant exchange rates, primarily driven by immunology and recent launches [13] - New launches contributed €1.8 billion in sales, accounting for 15% of total sales, with Dupixent sales growing by 26% this quarter [6][13] - Vaccine sales were €3.4 billion, down from the previous year due to competitive price pressure and lower flu immunization rates [8] Market Data and Key Metrics Changes - Sales outside the U.S. grew by 21%, exceeding €1 billion in the quarter [8] - Dupixent sales in the U.S. surpassed €3 billion, maintaining leadership in both new and total prescriptions across established indications [7] Company Strategy and Development Direction - The company aims to improve access to treatments and lower prices for patients, as demonstrated by the expansion of its patient affordability program for insulins [5][11] - The company is focused on advancing its innovative pipeline, with multiple regulatory submissions and approvals expected in the coming years [18][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business outlook for the remainder of the year and reiterated full-year 2025 sales guidance [4] - The company anticipates maintaining strong earnings momentum with 9% sales growth and low double-digit business EPS growth at constant exchange rates [15][16] Other Important Information - The company has completed acquisitions of Drensbios DR0201, Vigil Neuroscience, and Blueprint Medicines, which are factored into the guidance [15] - The company is committed to capital allocation across organic growth, selective acquisitions, dividends, and opportunistic share buybacks [17] Q&A Session Summary Question: Update on Poly-SPMS regulatory debate and confidence in resolving FDA questions - Management confirmed ongoing conversations with the FDA and looks forward to the PDUFA date of December 28 [31] Question: Update on U.S. policy conversations - Management stated that dialogues with the U.S. government have been ongoing and focused on demonstrating the value the company can bring [38] Question: Q4 ordering trends for Bayfortis - Management confirmed expectations for Q4 to be in line with Q3 performance and emphasized efforts to increase vaccination coverage rates [42][45] Question: 2027 guidance and potential levers to mitigate EBIT gap - Management acknowledged a significant R&D reimbursement decrease in 2027 but expressed confidence in maintaining profitability despite the gap [50][52] Question: Update on relipiravir and timing dynamics - Management indicated that patient recruitment is affecting timelines for CIDP studies, with results expected in the future [62] Question: Dupixent development around COPD and gross to net dynamics - Management highlighted strong growth in COPD and discussed the impact of payer groups on gross to net dynamics [81]

Financial Data and Key Metrics Changes - In Q3 2025, Sanofi reported sales of €12.4 billion, a 7% increase compared to the previous year [5][17] - Dupixent achieved quarterly sales of €4 billion for the first time, reflecting a 26% growth [8][17] - Business EPS reached €2.91, a robust growth of $0.19 or 13% compared to Q3 2024 [20] - The gross margin increased by 2.3 percentage points, driven by improved product mix and productivity gains [18][20] Business Line Data and Key Metrics Changes - New product launches contributed €1.8 billion in sales, growing over 40% and representing 15% of total sales [6][17] - Vaccine sales were €3.4 billion, reflecting competitive price pressure and lower flu immunization rates [11][17] - Dupixent's sales outside the U.S. grew by 21%, exceeding €1 billion in the quarter [10][17] Market Data and Key Metrics Changes - In the U.S., Dupixent sales surpassed €3 billion, maintaining leadership in both new and total prescriptions [9][10] - The vaccine business faced challenges due to lower flu vaccination rates and competitive pricing, particularly in Germany [11][17] Company Strategy and Development Direction - Sanofi aims to improve access to treatments and lower prices for patients, exemplified by the expansion of its patient affordability program for insulins [6][15] - The company is focused on advancing its innovative pipeline, with multiple regulatory submissions and approvals expected in the coming years [24][36] - Sanofi's capital allocation policy emphasizes investing in organic growth, pursuing selective acquisitions, and maintaining progressive dividends [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business outlook for the remainder of the year, reiterating full-year sales guidance [5][20] - The company is navigating competitive pressures in the vaccine market while continuing to innovate in respiratory virus protection [13][14] - Management highlighted the importance of ongoing dialogue with U.S. policymakers to enhance treatment access [6][44] Other Important Information - Sanofi has treated over 1 million patients for noncommunicable diseases in low and middle-income countries since 2021 [15] - The company is expanding its Insulin's Value Savings Program in the U.S. to ensure affordability for patients [15] Q&A Session Summary Question: Update on TOLI SMS regulatory debates and confidence in resolving FDA questions - Management confirmed ongoing discussions with the FDA and submitted datasets, looking forward to the PDUFA date of December 28 [40] Question: Updates on U.S. administration conversations regarding policy - Management stated that dialogues with the U.S. government have been ongoing, focusing on demonstrating the value of their treatments [44] Question: Impact of inventory carryover on Q4 orders and competition - Management confirmed expectations for Q4 to be similar in performance to Q3, with a focus on increasing vaccination coverage rates [50][51] Question: Insights on Dupixent's gross margin and COPD launch - Management noted strong growth from various sources, including foundational indications and new launches, with Dupixent's gross margin benefiting from improved manufacturing processes [90][91] Question: Future M&A strategy and vaccine trends - Management emphasized the importance of strategic fit and scientific differentiation in potential acquisitions, while also addressing vaccine fatigue trends [108]

Company Overview - PT Astra Agro Lestari Tbk is a subsidiary of Astra International and is one of the largest oil palm players in Indonesia with nearly 40 years of operational experience [1] - The company operates oil palm plantations across Sumatra, Kalimantan, and Sulawesi, covering a total area of approximately 285,000 hectares [1] Performance Metrics - The company achieved a Profitable Growth rank of 4, an improvement from the previous period's rank of 6, indicating above-average performance compared to 540 large consumer staples companies globally [5] - The Profitability rank improved to 5 from the prior period's 6, reflecting average performance relative to peers [5] - The Growth rank increased to 2 from the previous period's 3, showcasing world-class performance compared to industry peers [5]

RT Bloomberg Live (@BloombergLive)What does it take for organizations to be agile and deliver profitable growth? Michelle Boston joins #FutureReadyBiz to discuss Bank of America's continuous transformation.Register here to join us in NY on 11/13: https://t.co/qDZ2o3ogVg https://t.co/KW8rUhUH0d ...

Core Insights - Chow Tai Fook Jewellery Group Limited is a Hong Kong-based company specializing in the design, manufacture, and retail of fine jewelry, including gold, diamonds, and platinum [1] - The company operates a vast network of stores primarily in Greater China and is known for its flagship brands such as CHOW TAI FOOK, HEARTS ON FIRE, and ENZO [1] Performance Metrics - The company holds a Profitable Growth rank of 4, which is consistent with the previous period's rank, indicating above-average performance compared to 910 large consumer discretionary companies worldwide [4] - The Profitability rank is 3, which is better than its Growth rank of 7, and this rank has remained the same compared to the prior period [4] - The Growth rank of 7 has also remained unchanged from the previous period, reflecting below-average performance compared to peers [4]

Core Points - Broadwind has received $11 million in new tower orders from a leading global wind turbine manufacturer, which will be manufactured at its Abilene, Texas facility and fulfilled in the first quarter of 2026 [1][2] - The company aims to increase utilization across its precision manufacturing system, focusing on throughput optimization and asset efficiency to drive improved operating leverage and profitable growth in core power generation markets [2] Company Overview - Broadwind (Nasdaq: BWEN) is a precision manufacturer of structures, equipment, and components for clean tech and specialized applications, with facilities throughout the U.S. [2]

Company Overview - Petronas Dagangan Berhad is the petrol retailer and marketing subsidiary of Petronas, Malaysia's national oil and gas conglomerate, and one of the largest energy companies globally [1] - The company holds the number one market share in the petrol market in Malaysia, focusing all its business operations within the country [1] Performance Metrics - The company achieved a Profitable Growth rank of 2, maintaining the same rank as the prior period, indicating World Class performance compared to 310 large energy companies worldwide [5] - The Profitability rank of 2 was consistent with its Growth rank of 2, reflecting strong performance in both profitability and growth metrics [5] - The Growth rank improved to 2 from the previous period's 3, showcasing an upward trend in growth performance compared to peers [5]